TransMedics is executing a strategic debt-funded capacity expansion, with total debt rising from $518.3M in 2024Q4 to $867.7M in 2026Q2 and PPE surging to $702.9M, positioning for long-term organ transplant volume growth. However, revenue growth has decelerate...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.44-11.2% vs $0.50 | $190M+3.2% vs $184M |
Q2 2026 May 5, 2026 | $0.30-51.6% vs $0.62 | $174M-0.3% vs $174M |
Q1 2026 Feb 24, 2026 | $0.57+39.0% vs $0.41 | $161M+3.5% vs $155M |
Q4 2025 Oct 29, 2025 | $0.66+78.4% vs $0.37 | $144M-7.5% vs $155M |
TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares shot up 4.5% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $89.15 and last traded at $89.7060. 308,922 shares traded hands during trading, a decline of 70% from the average daily volume of 1,029,492
These companies' sell-offs may have gone too far.
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Benchmark TMDX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for TransMedics Group, Inc. (TMDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $88.07 | $3.04B | 18.08 | 37.13% | 31.43% | 54.24% | — | |
| $2.47 | $228.9M | -4.57 | — | — | -30.07% | — | |
| $21.70 | $5.92B | 38.62 | 3.21% | 10.99% | 8.94% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $78.49 | $4.31B | -17.64 | 10.74% | 12.82% | 15.41% | — | |
| $58.83 | $2.99B | -245.13 | 14.88% | 1.85% | 2.14% | — |
TransMedics Group, Inc. (TMDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
TransMedics Group, Inc. (TMDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 21, 2026·SEC
May 5, 2026·SEC
Get notified when TMDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TransMedics Group, Inc. (TMDX) stock FAQ — growth, dividends, profitability & financials explained
TransMedics Group, Inc. (TMDX) reported $668.5M in revenue for fiscal year 2025. This represents a 10666% increase from $6.2M in 2016.
TransMedics Group, Inc. (TMDX) grew revenue by 37.1% over the past year. This is strong growth.
Yes, TransMedics Group, Inc. (TMDX) is profitable, generating $151.7M in net income for fiscal year 2025 (31.4% net margin).
TransMedics Group, Inc. (TMDX) has a return on equity (ROE) of 54.2%. This is excellent, indicating efficient use of shareholder capital.
TransMedics Group, Inc. (TMDX) generated $66.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
